<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912756</url>
  </required_header>
  <id_info>
    <org_study_id>STOP-IC</org_study_id>
    <nct_id>NCT00912756</nct_id>
  </id_info>
  <brief_title>Sufficient Treatment of Peripheral Intervention by Cilostazol</brief_title>
  <acronym>STOP-IC</acronym>
  <official_title>Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Rosai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association for Establishment of Ebvidence in Interventions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kansai Rosai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, Nanto et al. reported that cilostazol effectively prevented restenosis in a
      retrospective analysis of 121 femoropopliteal artery lesions in percutaneous transluminal
      angioplasty (PTA) patients who had undergone PTA. In a prospective 3-year follow-up study in
      127 patients with similar diseases, the patency rate was significantly higher in the
      cilostazol group than in the ticlopidine group. It was also found that cilostazol markedly
      inhibited restenosis during the first 1-year period following endovascular therapy when
      restenosis is most frequently observed. In addition, there have been sporadic reports that
      cilostazol was effective in preventing post-stenting restenosis in the coronary artery area.

      Based on these results, this multicenter study is going to be conducted to prospectively
      evaluate the usefulness of cilostazol in lower limb endovascular therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic restenosis rate</measure>
    <time_frame>12 months +- 1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arteriosclerosis Obliterans</condition>
  <arm_group>
    <arm_group_label>1cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>200 mg/day BID</description>
    <arm_group_label>1cilostazol</arm_group_label>
    <arm_group_label>2aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient criteria:

          -  Chronic arteriosclerosis obliterans afflicting the femoropopliteal artery area*

          -  Patients who can be monitored for at least 2 years after surgery

        Lesion criteria:

          -  Angiographically-confirmed new significant superficial femoral artery stenosis or
             occlusive lesions that are 30 cm long or less if stented

          -  At least 1 arterial runoff below the knee; stenosis lesions not limiting flow may be
             included.

          -  Occlusive lesions may be included.

        Exclusion criteria:

          -  Patients with or at risk of hemorrhagic complications or patients with bleeding
             tendency

          -  Patients with congestive cardiac failure

          -  Patients with a drug-eluting stent

          -  Patients with acute lower limb ischemia

          -  Patients with creatinine of 2 mg/dL or more(without dialysis)

          -  patients with a history of serious adverse reaction such as leukopenia, hepatic
             dysfunction, or renal dysfunction, or hypersensitivity to any component of the study
             drug.

        Lesion criteria:

          -  Remnant inflow

          -  Severe calcification

          -  No arterial runoff below the knee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Iida</last_name>
    <role>Study Director</role>
    <affiliation>Kansai Rosai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osamu Iida</last_name>
    <phone>+81-6-6416-1221</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shinsuke Nanto</last_name>
    <phone>+81-6-6416-1221</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shinkoga Hospital</name>
      <address>
        <city>Kurume city</city>
        <state>Fukuoka</state>
        <zip>8308577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shintani Yoshiaki</last_name>
      <phone>81-942-38-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hopital</name>
      <address>
        <city>Nishinomiya city</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daizo Kawasaki</last_name>
      <phone>0798-45-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Kanazawa Cardiovascular Hospital</name>
      <address>
        <city>Kanazawa city</city>
        <state>Ishikawa</state>
        <zip>920-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taketsugu Tsuchiya</last_name>
      <phone>81-76-253-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology,Naganoken Koseiren Shinonoi</name>
      <address>
        <city>Nagano-city</city>
        <state>Nagano</state>
        <zip>3888004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norihiko Shinozaki</last_name>
      <phone>81-26-292-2261</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Omihachiman city</city>
        <state>Shiga</state>
        <zip>523-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kan Zen</last_name>
      <phone>81-748-33-3151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital and seven others</name>
      <address>
        <city>Amagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Osamu Iida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Kishiwada</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiaki Yokoi</last_name>
      <phone>81-72-445-9915</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyusy</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyoshi Yokoi</last_name>
      <phone>81-93-921-2231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yusuke Miyashita</last_name>
      <phone>81- 263-35-4600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caress Sapporo Tokeidai Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazushi Urasawa</last_name>
      <phone>81-11-251-1221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoto Inoue</last_name>
      <phone>81-22-222-6181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kikuna Memorial Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Miyamoto</last_name>
      <phone>81-45-402-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama- City Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisuke Hirano</last_name>
      <phone>81-45-576-3000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>July 21, 2010</last_update_submitted>
  <last_update_submitted_qc>July 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Osamu Iida</name_title>
    <organization>Kansai Rosai Hospital</organization>
  </responsible_party>
  <keyword>endovascular therapy</keyword>
  <keyword>restenosis</keyword>
  <keyword>cilostazol</keyword>
  <keyword>femoropopliteal artery lesions</keyword>
  <keyword>Chronic arteriosclerosis obliterans afflicting the femoropopliteal artery area</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

